170 related articles for article (PubMed ID: 33430343)
1. Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.
Shang C; Hassan B; Haque M; Song Y; Li J; Liu D; Lipke E; Chen W; Giuriato S; Lai R
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430343
[TBL] [Abstract][Full Text] [Related]
2. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.
Wu C; Zhang HF; Gupta N; Alshareef A; Wang Q; Huang YH; Lewis JT; Douglas DN; Kneteman NM; Lai R
J Hematol Oncol; 2016 Nov; 9(1):120. PubMed ID: 27821172
[TBL] [Abstract][Full Text] [Related]
3. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
[TBL] [Abstract][Full Text] [Related]
5. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
[TBL] [Abstract][Full Text] [Related]
6. The Dual Role of Autophagy in Crizotinib-Treated ALK
Espinos E; Lai R; Giuriato S
Cells; 2021 Sep; 10(10):. PubMed ID: 34685497
[TBL] [Abstract][Full Text] [Related]
7. High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells.
Sorrentino D; Frentzel J; Mitou G; Blasco RB; Torossian A; Hoareau-Aveilla C; Pighi C; Farcé M; Meggetto F; Manenti S; Espinos E; Chiarle R; Giuriato S
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066037
[TBL] [Abstract][Full Text] [Related]
8. High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.
Alshareef A; Gupta N; Zhang HF; Wu C; Haque M; Lai R
Sci Rep; 2017 Dec; 7(1):16863. PubMed ID: 29203817
[TBL] [Abstract][Full Text] [Related]
9. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.
Pilling AB; Kim J; Estrada-Bernal A; Zhou Q; Le AT; Singleton KR; Heasley LE; Tan AC; DeGregori J; Doebele RC
Oncotarget; 2018 Feb; 9(10):8823-8835. PubMed ID: 29507657
[TBL] [Abstract][Full Text] [Related]
10. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report.
Harrer DC; Menhart K; Mayer S; Herr W; Reichle A; Vogelhuber M
Front Oncol; 2020; 10():585830. PubMed ID: 33134180
[TBL] [Abstract][Full Text] [Related]
11. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
13. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
15. A novel ALK inhibitor ZYY inhibits Karpas299 cell growth in vitro and in a mouse xenograft model and induces protective autophagy.
Shen J; Wang J; Du J; Wang L; Zhou X; Chang X; Li Z; Zhai X; Zuo D; Wu Y
Toxicol Appl Pharmacol; 2019 Nov; 383():114781. PubMed ID: 31618659
[TBL] [Abstract][Full Text] [Related]
16. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
18. MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report.
Rihawi K; Alfieri R; Fiorentino M; Fontana F; Capizzi E; Cavazzoni A; Terracciano M; La Monica S; Ferrarini A; Buson G; Petronini PG; Ardizzoni A
Transl Oncol; 2019 Jan; 12(1):116-121. PubMed ID: 30290287
[TBL] [Abstract][Full Text] [Related]
19. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
Uchihara Y; Ueda F; Tago K; Nakazawa Y; Ohe T; Mashino T; Yokota S; Kasahara T; Tamura H; Funakoshi-Tago M
PLoS One; 2017; 12(8):e0183003. PubMed ID: 28806414
[TBL] [Abstract][Full Text] [Related]
20. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
